VOLUNTARY ANNOUNCEMENT - "BORTEZOMIB FOR INJECTION" OBTAINS DRUG REGISTRATION APPROVAL

— 1 — Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement. CSPC PharmaCeutiCal GrouP limited ʮ ̡ (Incorporated in Hong Kong with limited liability) (Stock Code: 1093) VoluNtarY aNNouNCeme Nt “bortezomib F or iNjeCtio N” obtaiNS druG reG iStratio N aPP ro Val The board of directors (the “ board”) of CSPC Pharmaceutical Group Limited (the “ Company ”, together with its subsidiaries, the “Group”) is pleased to announce that the “Bortezomib for Injection (3.5mg)” (the “ Product ”) developed by CSPC Ouyi Pharmaceutical Co., Ltd.* €ͩᖹණྠ ʮ̡, a subsidiary of the Company, has obtained drug registration approval granted by the National Medical Products Administration of the People’s Republic of China, being the first generic drug of this type deemed as passing the consistency of quality and efficacy evaluation in China. Bortezomib is the world’s first oncology drug targeting the proteasome in targeted therapy. It is indicated for 1) multiple myeloma: used in combination with melphalan and prednisone (MP regimen) for the treatment of patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with bone marrow transplantation; or used as monotherapy for the treatment of patients with relapsed multiple myeloma who have received at least one prior therapy; 2) mantle cell lymphoma: used for the treatment of patients with relapsed or refractory mantle cell lymphoma who have received at least one prior therapy. Bortezomib has become the first-line targeted drug for the treatment of multiple myeloma. The approval of the Product further enriches the Group’s product portfolio and also enhances the Group’s development in the oncology field. By order of the Board CSPC Pharmaceutical Group limited Cai dongchen Chairman Hong Kong, 23 June 2020 — 2 — As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LU Hua, Dr. LI Chunlei, Dr. WANG Qingxi and Mr. CHAK Kin Man as executive directors; Mr. LEE Ka Sze, Carmelo as non- executive director; and Mr. CHAN Siu Keung, Leonard, Mr. WANG Bo, Prof. LO Yuk Lam, Dr. YU Jinming and Mr. CHEN Chuan as independent non-executive directors. * For identification purpose only.

The release as fetched from its publisher. irasia.com ↗